Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Varkaris

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
The Prostate|February 2, 2013
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancerFarshid Dayyani, Andreas Varkaris, John C Araujo, et al.
International Journal of Cancer|March 26, 2013
Ligand-independent activation of MET through IGF-1/IGF-1R signalingAndreas Varkaris, Sanchaika Gaur, Nila U Parikh, et al.
Cancer Research|January 9, 2023
WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor GrowthKeshan Wang, Fen Ma, Seiji Arai, et al.
Anticancer Research|April 22, 2011
Time to castration resistance is an independent predictor of castration-resistant prostate cancer survivalEvangelos Bournakis, Eleni Efstathiou, Andreas Varkaris, et al.
Molecular Cancer Therapeutics|June 19, 2024
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate CancerMannan Nouri, Andreas Varkaris, Maya Ridinger, et al.
JTO Clinical and Research Reports|June 9, 2021
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsPedro E N S Vasconcelos, Carol Gergis, Hollis Viray, et al.
Urology|January 25, 2011
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancerIoannis Mountzios, Evangelos Bournakis, Eleni Efstathiou, et al.
Nature Communications|February 14, 2026
FOXJ1 mediates taxane resistance through regulation of microtubule dynamicsFang Xie, Ada Gjyrezi, Daniel Fein, et al.
Oncotarget|August 28, 2015
Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagySanchaika Gaur, Yunfei Wen, Jian H Song, et al.
British Journal of Cancer|January 15, 2019
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancerAndreas Varkaris, Anastasia Katsiampoura, Jennifer S Davis, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
The Prostate|February 2, 2013
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancerFarshid Dayyani, Andreas Varkaris, John C Araujo, et al.
International Journal of Cancer|March 26, 2013
Ligand-independent activation of MET through IGF-1/IGF-1R signalingAndreas Varkaris, Sanchaika Gaur, Nila U Parikh, et al.
Cancer Research|January 9, 2023
WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor GrowthKeshan Wang, Fen Ma, Seiji Arai, et al.
Anticancer Research|April 22, 2011
Time to castration resistance is an independent predictor of castration-resistant prostate cancer survivalEvangelos Bournakis, Eleni Efstathiou, Andreas Varkaris, et al.
Molecular Cancer Therapeutics|June 19, 2024
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate CancerMannan Nouri, Andreas Varkaris, Maya Ridinger, et al.
JTO Clinical and Research Reports|June 9, 2021
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsPedro E N S Vasconcelos, Carol Gergis, Hollis Viray, et al.
Urology|January 25, 2011
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancerIoannis Mountzios, Evangelos Bournakis, Eleni Efstathiou, et al.
Nature Communications|February 14, 2026
FOXJ1 mediates taxane resistance through regulation of microtubule dynamicsFang Xie, Ada Gjyrezi, Daniel Fein, et al.
Oncotarget|August 28, 2015
Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagySanchaika Gaur, Yunfei Wen, Jian H Song, et al.
British Journal of Cancer|January 15, 2019
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancerAndreas Varkaris, Anastasia Katsiampoura, Jennifer S Davis, et al.
Pageof 4